Prognostic significance of bone metastases (BM) and bisphosphonate (BIS) therapy in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs).
Rana R. McKay
Consultant or Advisory Role - Pfizer (U)
Xun Lin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Julia Jane Perkins
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ronit Simantov
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Toni K. Choueiri
Consultant or Advisory Role - Pfizer